6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      RNase L targets distinct sites in influenza A virus RNAs.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Influenza A virus (IAV) infections are influenced by type 1 interferon-mediated antiviral defenses and by viral countermeasures to these defenses. When IAV NS1 protein is disabled, RNase L restricts virus replication; however, the RNAs targeted for cleavage by RNase L under these conditions have not been defined. In this study, we used deep-sequencing methods to identify RNase L cleavage sites within host and viral RNAs from IAV PR8ΔNS1-infected A549 cells. Short hairpin RNA knockdown of RNase L allowed us to distinguish between RNase L-dependent and RNase L-independent cleavage sites. RNase L-dependent cleavage sites were evident at discrete locations in IAV RNA segments (both positive and negative strands). Cleavage in PB2, PB1, and PA genomic RNAs suggests that viral RNPs are susceptible to cleavage by RNase L. Prominent amounts of cleavage mapped to specific regions within IAV RNAs, including some areas of increased synonymous-site conservation. Among cellular RNAs, RNase L-dependent cleavage was most frequent at precise locations in rRNAs. Our data show that RNase L targets specific sites in both host and viral RNAs to restrict influenza virus replication when NS1 protein is disabled.

          Related collections

          Author and article information

          Journal
          J. Virol.
          Journal of virology
          1098-5514
          0022-538X
          Mar 2015
          : 89
          : 5
          Affiliations
          [1 ] Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
          [2 ] Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio, USA.
          [3 ] Department of Microbiology, Department of Medicine, Division of Infectious Diseases, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
          [4 ] Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado, USA.
          [5 ] Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado, USA david.barton@ucdenver.edu.
          Article
          JVI.02953-14
          10.1128/JVI.02953-14
          4325751
          25540362
          a1547070-bb12-46d9-b172-80267a326a5f
          Copyright © 2015, American Society for Microbiology. All Rights Reserved.
          History

          Comments

          Comment on this article